Notices. Notice
444 words·~2 min read·
/register/2016/09/19/2016-22376A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2015-N-2489] Receipt of Notice That a Patent Infringement Complaint Was Filed Against a Biosimilar Applicant AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration
(FDA)is publishing notice that an applicant for a proposed biosimilar product notified FDA that a patent infringement action was filed in connection with the applicant's biologics license application (BLA). Under the Public Health Service Act (PHS Act), an applicant for a proposed biosimilar product or interchangeable product must notify FDA within 30 days after the applicant was served with a complaint in a patent infringement action described under the PHS Act. FDA is required to publish notice of the complaint in the **Federal Register** . FOR FURTHER INFORMATION CONTACT: Daniel Orr, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6208, Silver Spring, MD 20993-0002, 240-402-0979, *daniel.orr@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) was enacted as part of the Patient Protection and Affordable Care Act (Pub. L. 111-148) on March 23, 2010. The BPCI Act amended the PHS Act and created an abbreviated licensure pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed biological reference product. Section 351(k) of the PHS Act (42 U.S.C. 262(k)), added by the BPCI Act, describes the requirements for a BLA for a proposed biosimilar product or a proposed interchangeable product (351(k) BLA). Section 351( *l* ) of the PHS Act, also added by the BPCI Act, describes certain procedures for exchanging patent information and resolving patent disputes between a 351(k) BLA applicant and the holder of the BLA reference product. If a 351(k) applicant is served with a complaint for a patent infringement described in section 351( *l* )(6) of the PHS Act, the applicant is required, under section 351( *l* )(6)(C) of the PHS Act, to provide the FDA with notice and a copy of the complaint within 30 days of service. FDA is required to publish notice of a complaint received under section 351( *l* )(6)(C) of the PHS Act in the **Federal Register** . FDA has received notice of the following complaint under section 351( *l* )(6)(C) of the PHS Act: *Amgen* v. *Sandoz,* 3:16-cv-02581 (N.D. Cal., filed May 12, 2015). FDA has only a ministerial role in publishing notice of a complaint received under section 351( *l* )(6)(C) of the PHS Act, and does not perform a substantive review of the complaint. Dated: September 12, 2016. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2016-22376 Filed 9-16-16; 8:45 am]
Connectionstraces to 1
Traces to 1 document
1 reference not yet in our index
- Pub. L. 111-148
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources